Organization | Getz Pharma

Getz Pharma Report issue

For profit Phase 4

Founded: Karachi Pakistan (1995)

Status: No NME R&D (1995)

Organization Overview

First Clinical Trial

2004

NCT00502970

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Getz Pharma | Getz Pharma Pakistan

Active Ingredients

Drugs in Phase 4 Trials (16)

allopurinol (zyloprim) (1 trial)

apixaban (eliquis) (1 trial)

empagliflozin (jardiance) (4 trials)

ertugliflozin (Steglatro) (1 trial)

febuxostat (uloric) (1 trial)

insulin human (humulin) (1 trial)

interferon alpha-2b (Intron-A) (3 trials)

metformin (glucophage) (1 trial)

nitazoxanide (Alinia) (1 trial)

pioglitazone (actos) (1 trial)

ribavirin (virazole) (3 trials)

rivaroxaban (xarelto) (1 trial)

sitagliptin (januvia) (1 trial)

tamsulosin (flomax) (1 trial)

vildagliptin (1 trial)

warfarin (coumadin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Chronic Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hyperuricemia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial APIs: 16